{"id":"NCT04039022","sponsor":"Axsome Therapeutics, Inc.","briefTitle":"Open-Label Safety Study of AXS-05 in Subjects With Depression","officialTitle":"An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-08","primaryCompletion":"2020-10-23","completion":"2020-10-23","firstPosted":"2019-07-31","resultsPosted":"2022-10-12","lastUpdate":"2022-10-12"},"enrollment":876,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder","Treatment Resistant Depression","Depression"],"interventions":[{"type":"DRUG","name":"AXS-05 (dextromethorphan and bupropion) oral tablets","otherNames":[]}],"arms":[{"label":"AXS-05","type":"EXPERIMENTAL"}],"summary":"An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.","primaryOutcome":{"measure":"Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05","timeFrame":"Up to 12 months","effectByArm":[{"arm":"AXS-05","deltaMin":505,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":51,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":876},"commonTop":["Dizziness","Nausea","Headache","Dry mouth","Decreased appetite"]}}